Stress & Anxiety Relief Peptide Stack 2026: Selank, Oxytocin, DSIP & GLP-1 Research Protocol

# Stress & Anxiety Relief Peptide Stack 2026: Selank, Oxytocin, DSIP & GLP-1 Research Protocol

> Research Disclaimer: This information is for research purposes only. The compounds described are research chemicals and/or regulated medications not approved for anxiety or stress treatment in humans outside of clinical settings. This is not medical advice. Do not self-administer any compound without appropriate medical and legal guidance.

Overview

The hypothalamic-pituitary-adrenal (HPA) axis is the body's master stress response system. When activated chronically — as in prolonged psychological stress, anxiety disorders, or burnout — it produces sustained cortisol elevation, suppressed immune function, disrupted sleep architecture, and progressive dysregulation of neurotransmitter systems governing mood and cognition. Peptide research targeting stress and anxiety biology has increasingly focused on compounds that can modulate HPA axis output at multiple levels simultaneously.

This research protocol examines four compounds with distinct, complementary anti-stress mechanisms:

• •Selank — anxiolytic heptapeptide derived from tuftsin; GABAergic and serotonergic modulation
• •Oxytocin — hypothalamic neuropeptide that directly suppresses HPA axis activation through OXTR signaling
• •DSIP (Delta Sleep-Inducing Peptide) — nonapeptide that normalizes cortisol rhythms and improves sleep architecture
• •Semaglutide / GLP-1 receptor agonists — emerging research on vagal tone, amygdala GLP-1R, and stress-eating biology

Together, these compounds address anxiolytic signaling, HPA axis restraint, sleep-cortisol normalization, and the stress-metabolic interface — a multi-level approach to HPA axis dysregulation research.

Why Stack These Peptides? Mechanistic Rationale

Chronic stress dysregulation is maintained by mutually reinforcing feedback loops: elevated cortisol suppresses sleep, disrupted sleep elevates cortisol, anxiety increases HPA reactivity, and stress-driven eating perpetuates metabolic signals that amplify stress response. Interrupting these loops at multiple points simultaneously may produce synergistic research outcomes:

Selank acts on the day-to-day anxiolytic axis — reducing basal anxiety and HPA reactivity through GABAergic enhancement and enkephalin metabolism modulation. It's the "mood floor" stabilizer in this stack.

Oxytocin directly suppresses CRH (corticotropin-releasing hormone) release from the paraventricular nucleus, functioning as an endogenous HPA axis brake. Social bonding activates oxytocin; oxytocin then reduces the HPA response to subsequent stressors — a well-documented positive feedback loop that this stack aims to pharmacologically replicate in research models.

DSIP targets the chronobiological component of HPA dysregulation — normalizing the cortisol awakening response, improving slow-wave sleep (the phase of greatest GH secretion and cortisol clearance), and potentially resetting the HPA circadian rhythm.

GLP-1/Semaglutide represents the newest dimension: research on GLP-1 receptors in the amygdala and vagal nucleus suggests that GLP-1R agonists modulate the stress-eating response and reduce anxiety-driven food intake, with emerging data on direct amygdala anxiolytic effects.

Compound Profiles

Selank — Thr-Lys-Pro-Arg-Pro-Gly-Pro (Tuftsin Analog)

Molecular weight: 751.9 Da

Structure: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids)

Origin: Synthetic analog of tuftsin (Thr-Lys-Pro-Arg), extended with Pro-Gly-Pro

Administration: Intranasal (primary); subcutaneous also studied

Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an endogenous tetrapeptide from IgG immunoglobulin — extended to improve CNS activity and duration:

Anxiolytic mechanism: Selank's primary anxiolytic mechanism appears to involve modulation of GABAergic neurotransmission, specifically through interaction with GABAA receptor benzodiazepine binding sites. Unlike classical benzodiazepines, Selank does not produce sedation, tolerance, or dependence at research doses — which has made it a subject of considerable interest as a potential anxiolytic model compound.

Enkephalin metabolism: A documented mechanism of Selank is its inhibition of enkephalinase (neutral endopeptidase) activity, which increases the synaptic half-life of endogenous enkephalins. Enkephalins are endogenous opioid neuropeptides that modulate pain, stress, and mood through δ-opioid receptors.

Serotonin and BDNF upregulation: Research from Russian groups documents Selank-induced increases in serotonin levels in limbic areas and upregulation of BDNF in the hippocampus and amygdala — effects that parallel the action of established antidepressants and anxiolytics.

HPA axis modulation: In animal models of chronic restraint stress, Selank reduces plasma ACTH and corticosterone responses to acute stress challenges, suggesting a dampening effect on HPA axis reactivity — complementary to Oxytocin's direct CRH suppression.

Immunomodulatory effects: Selank also demonstrates immunomodulatory effects (increasing IL-2, IL-6 production in T cells, improving natural killer cell activity) — relevant because chronic stress dramatically impairs immune function.

Research parameters: Intranasal doses in animal and human research typically range from 25–300 mcg per administration; 1–2× daily.

See full research profile: Selank

---

Oxytocin — The "Bonding Hormone" HPA Brake

Molecular weight: 1,007.2 Da

Structure: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (cyclic nonapeptide via disulfide bond)

Receptor: OXTR (oxytocin receptor) — Gq-coupled GPCR

Status: FDA-approved drug (Pitocin); research-grade peptide widely available

Oxytocin is one of the most clinically important and intensively researched neuropeptides in biology, with direct relevance to stress modulation:

HPA axis suppression: Oxytocinergic neurons in the paraventricular nucleus (PVN) directly inhibit CRH-producing neurons, providing one of the most potent endogenous brakes on the stress response axis. Multiple research groups have documented that intranasal oxytocin administration in humans reduces cortisol responses to psychosocial stress (Trier Social Stress Test), reduces amygdala reactivity to threatening stimuli, and improves trust and social approach behavior.

Social stress buffering: Oxytocin's role in buffering social stress is one of the most reproducible findings in human neuroendocrinology. The HPA response to social threat is significantly blunted when endogenous or exogenous oxytocin is elevated — a mechanism that explains why social support reduces stress physiology.

GABA modulation: In early development, oxytocin helps switch GABAergic signaling from excitatory to inhibitory — an effect with implications for adult anxiety research. In adult models, oxytocin enhances inhibitory GABAergic tone in limbic circuits, contributing to its anxiolytic effects.

Sleep and cortisol rhythm: Oxytocin receptors are expressed in the suprachiasmatic nucleus (SCN), the brain's circadian clock. OXT signaling influences the amplitude and timing of the cortisol awakening response (CAR). Research suggests that oxytocinergic tone during sleep contributes to the restoration of normal HPA circadian rhythmicity.

Complementarity with Selank: Selank reduces basal HPA reactivity through GABAergic mechanisms; Oxytocin reduces HPA reactivity through direct CRH suppression and social-stress-specific pathways. These are independent, additive mechanisms in research models.

Research parameters: Intranasal: 8–40 IU per administration in human research (synthetic oxytocin). Subcutaneous: research models use weight-based dosing.

See full research profile: Oxytocin

---

DSIP — Delta Sleep-Inducing Peptide

Molecular weight: 848.9 Da

Structure: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (9 amino acids)

Primary effects: Sleep architecture improvement, cortisol normalization, opioid modulation

History: Discovered 1977 (Monnier & Collet), Swiss research

DSIP was first isolated from rabbit brain perfusate in 1977 by Marcel Monnier and colleagues. It received its name from its ability to induce delta wave (slow-wave) sleep in rabbit EEG studies. Subsequent research has revealed broader neuroendocrine effects:

Cortisol rhythm normalization: The most clinically relevant research on DSIP involves its effects on the cortisol awakening response (CAR) and HPA axis circadian rhythmicity. In human studies, DSIP administration normalizes elevated cortisol secretion in subjects with disordered stress response, reducing the pathological cortisol hypersecretion seen in burnout and chronic stress while not suppressing physiological morning cortisol rises.

ACTH and stress hormone modulation: DSIP demonstrates complex effects on the HPA axis — reducing ACTH secretion under stressful conditions while preserving baseline ACTH levels. This "stress-selective" HPA dampening is mechanistically distinct from corticosteroid therapy, which non-selectively suppresses the entire axis.

Sleep architecture effects: Beyond inducing slow-wave sleep, DSIP has been documented to increase the proportion of restorative deep sleep and to normalize sleep onset latency in models of insomnia. Improved sleep architecture is directly relevant to HPA axis normalization, as cortisol clearance and growth hormone secretion (which partially counterregulates cortisol) occur primarily during deep sleep.

Opioid system interaction: DSIP appears to modulate mu-opioid receptor signaling in limbic areas, which contributes to its stress-modulating effects. The interaction between DSIP and enkephalin systems creates a mechanistic connection to Selank (which also modulates enkephalin metabolism).

Pain modulation: Research has documented analgesic effects of DSIP in models of chronic pain — relevant because chronic pain is both a cause and consequence of HPA axis dysregulation.

Research parameters: IV and subcutaneous administration in human research; intranasal in some protocols. Doses in published human studies range from 0.01–30 mg, typically low doses (0.01–0.1 mg) being effective for sleep/HPA effects.

See full research profile: DSIP

---

GLP-1 / Semaglutide — Emerging Stress-Eating and Anxiety Biology

Molecular weight: Semaglutide: 4,113 Da (modified GLP-1 analog with C18 fatty acid)

Receptor: GLP-1R (GLP-1 receptor) — Gs-coupled GPCR

Status: FDA-approved (Ozempic, Wegovy) for type 2 diabetes and obesity

GLP-1 receptor agonists like semaglutide are primarily studied for metabolic and cardiovascular applications, but an emerging body of research documents significant CNS effects relevant to stress and anxiety research:

Amygdala GLP-1 receptors: GLP-1 receptors are expressed in the amygdala — the brain's central fear and stress response hub. Research by Farr et al. and colleagues at the NIH and multiple international groups has documented that GLP-1R agonist administration reduces anxiety-like behavior in rodent models (EPM, open field), decreases amygdala activation in response to threatening stimuli, and modulates fear memory consolidation.

Vagal-HPA interaction: The vagus nerve expresses GLP-1 receptors, and GLP-1 released from L-cells in the gut activates vagal afferents that project to the nucleus tractus solitarius (NTS) in the brainstem. The NTS sends projections to the PVN (the HPA axis origin), creating a gut-to-HPA signaling pathway. GLP-1R activation in this pathway may modulate HPA axis reactivity to gut-derived signals.

Stress-eating biology: GLP-1R agonists significantly reduce "emotional eating" and "stress-eating" — the consumption of palatable high-fat, high-sugar foods in response to stress. This effect appears to involve both peripheral satiety signaling and direct CNS effects on the reward and motivation circuits that drive stress-driven food seeking.

Cortisol and HPA axis data: Some human research has documented that GLP-1R agonist treatment modestly reduces cortisol awakening response and inflammatory markers in obese individuals — consistent with reduced chronic stress signaling.

Research parameters: Semaglutide research protocols follow FDA-approved dosing (0.25–2.4 mg subcutaneous weekly for obesity research). GLP-1 itself has a half-life of ~2 minutes; research with native GLP-1 uses IV infusion.

See full research profile: Semaglutide / GLP-1

Stack Protocol

Dosing Windows & Sequencing

Morning (6–8 AM):

• •DSIP: Morning administration aims to normalize the cortisol awakening response (CAR). DSIP given in the early morning window may attenuate the pathological cortisol spike seen in chronic stress subjects while preserving normal physiological CAR amplitude.

Midday:

• •Selank (intranasal): Midday dosing reduces HPA reactivity during peak social/work stress hours. The GABAergic anxiolytic effect has a duration of 4–8 hours in animal models; midday administration provides afternoon coverage.

Evening (5–8 PM, pre-social interaction or 1–2 hours before sleep):

• •Oxytocin (intranasal): Evening administration capitalizes on oxytocin's sleep and social bonding effects. Research shows intranasal oxytocin enhances slow-wave sleep, which directly suppresses cortisol secretion during the night. For research in social contexts, timing 15–45 min before social interaction leverages oxytocin's social stress buffering.

Weekly (subcutaneous):

• •Semaglutide: Weekly subcutaneous injection per FDA-approved dosing protocol. The metabolic and CNS stress-modulating effects of GLP-1R agonists accumulate over weeks, making weekly dosing appropriate.

Reconstitution Notes

Selank:

• •Reconstitute lyophilized Selank with sterile bacteriostatic water or sterile saline to 0.1–1 mg/mL for intranasal use
• •For intranasal nasal spray: dilute to 0.01–0.1 mg per 0.1 mL spray
• •Store at 4°C reconstituted; lyophilized at -20°C

Oxytocin:

• •Research-grade synthetic oxytocin: reconstitute with sterile saline or BAC water to desired concentration for intranasal (typically 40 IU/mL for 8 IU per 0.1 mL spray) or subcutaneous administration
• •Store at 4°C; stable reconstituted for 4–6 weeks under refrigeration

DSIP:

• •Reconstitute with sterile BAC water to 0.1–1 mg/mL
• •Low doses are used in research; careful volumetric handling required
• •Store at 4°C reconstituted; -20°C lyophilized; avoid freeze-thaw cycles

Semaglutide:

• •Follow FDA-approved Ozempic/Wegovy prescribing information for pen injector use
• •Research-grade lyophilized semaglutide: reconstitute with sterile BAC water to desired concentration

Storage Summary

Research Evidence Summary

Evidence quality in this stack varies by compound:

• •Selank: Strong Russian preclinical and clinical literature; GABAergic mechanism well-characterized. Awaits large Western RCT validation.
• •Oxytocin: One of the most extensively researched neuropeptides; intranasal effects on HPA axis and social stress are documented in multiple Western RCTs and meta-analyses.
• •DSIP: Rich preclinical literature; limited but positive human data on cortisol normalization and sleep architecture. Research interest renewed given HPA dysregulation focus in modern psychiatry.
• •GLP-1/Semaglutide: Substantial FDA-approved human data for metabolic effects; CNS stress/anxiety effects are emerging from preclinical research and secondary analyses of obesity trials.

No published trial has studied this four-compound combination. Individual compound mechanisms are well-established; their combination for HPA axis research is based on mechanistic complementarity.

Frequently Asked Questions

Q: Does Selank cause benzodiazepine-like dependence?

A: Research to date has not documented tolerance or dependence with Selank at research doses. The mechanism appears to modulate GABAergic tone rather than directly binding benzodiazepine sites with high affinity, which may explain the different side effect profile. However, long-term human safety data is limited.

Q: How quickly does intranasal oxytocin work for stress?

A: Human research typically shows measurable effects on cortisol and amygdala reactivity within 30–60 minutes of intranasal administration. Effects are transient, peaking at 30–90 minutes.

Q: Is DSIP still being researched?

A: Yes. DSIP research experienced a period of reduced activity in the 1990s but has been reinvigorated by growing interest in sleep-HPA axis connections, circadian biology, and peptide-based sleep interventions. Multiple research groups continue to investigate DSIP's mechanisms.

Q: Why include a GLP-1 agonist in an anxiety/stress stack?

A: The inclusion is based on emerging evidence for GLP-1R expression in the amygdala and vagal-HPA pathways, and the well-documented reduction in stress-eating behavior with GLP-1R agonist treatment. This is the most exploratory element of the stack and should be understood as a research hypothesis rather than established anxiolytic treatment.

Where to Source These Peptides

Compare verified suppliers for each compound in this stack:

• •Compare Selank suppliers
• •Compare Oxytocin suppliers
• •Compare DSIP suppliers
• •Compare Semaglutide suppliers

For research purposes only. Verify compound purity via third-party Certificate of Analysis before any research use.